Immuneering CorporationIMRXNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR-55.9%
5Y CAGR-12.5%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
-55.9%/yr
Annual compound
5Y CAGR
-12.5%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
20257.59%
2024-4.07%
20237.39%
202288.67%
2021165.98%
202014.81%
20190.00%